A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Dato-DXd|DRUG: Durvalumab|DRUG: Capecitabine|DRUG: Pembrolizumab
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo|SWOG Clinical Trials Partnerships